Literature DB >> 15289938

Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis.

M G Battelli1, S Musiani, L Buonamici, S Santi, M Riccio, N M Maraldi, T Girbés, F Stirpe.   

Abstract

Among two-chain ribosome-inactivating proteins (RIPs), volkensin is the most toxic to cells and animals, and is retrogradely axonally transported in the rat central nervous system, being an effective suicide transport agent. Here we studied the binding, endocytosis, intracellular routeing, degradation and exocytosis of this RIP. The interaction of volkensin with HeLa cells was compared to that of nigrin b, as an example of a type 2 RIP with low toxicity, and of ricin, as a reference toxin. Nigrin b and volkensin bound to cells with comparable affinity (approx. 10(-10) M) and had a similar number of binding sites (2 x 10(5)/cell), two-log lower than that reported for ricin. The cellular uptake of volkensin was lower than that reported for nigrin b and ricin. Confocal microscopy showed the rapid localization of volkensin in the Golgi stacks with a perinuclear localization similar to that of ricin, while nigrin b was distributed between cytoplasmic dots and the Golgi compartment. Consistently, brefeldin A, which disrupts the Golgi apparatus, protected cells from the inhibition of protein synthesis by volkensin or ricin, whereas it was ineffective in the case of nigrin b. Of the cell-released RIPs, 57% of volkensin and only 5% of ricin were active, whilst exocytosed nigrin b was totally inactive. Despite the low binding to, and uptake by, cells, the high cytotoxicity of volkensin may depend on (i) routeing to the Golgi apparatus, (ii) the low level of degradation, (iii) rapid recycling and (iv) the high percentage of active toxin remaining after exocytosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289938     DOI: 10.1007/s00018-004-4171-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  19 in total

1.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

4.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

Authors:  Roxana Mehran; Usman Baber; Philippe Gabriel Steg; Cono Ariti; Giora Weisz; Bernhard Witzenbichler; Timothy D Henry; Annapoorna S Kini; Thomas Stuckey; David J Cohen; Peter B Berger; Ioannis Iakovou; George Dangas; Ron Waksman; David Antoniucci; Samantha Sartori; Mitchell W Krucoff; James B Hermiller; Fayaz Shawl; C Michael Gibson; Alaide Chieffo; Maria Alu; David J Moliterno; Antonio Colombo; Stuart Pocock
Journal:  Lancet       Date:  2013-09-01       Impact factor: 79.321

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 7.  Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.

Authors:  Marc P Bonaca; Deepak L Bhatt; Eugene Braunwald; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Peter Held; Eva C Jensen; Marc S Sabatine
Journal:  Am Heart J       Date:  2014-01-06       Impact factor: 4.749

8.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Authors:  Deepak L Bhatt; Marcus D Flather; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Liz Fabry-Ribaudo; Tingfei Hu; Eric J Topol; Keith A A Fox
Journal:  J Am Coll Cardiol       Date:  2007-04-11       Impact factor: 24.094

Review 9.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  JAMA       Date:  2012-12-19       Impact factor: 56.272

10.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

Authors:  Jean-Philippe Collet; Thomas Cuisset; Grégoire Rangé; Guillaume Cayla; Simon Elhadad; Christophe Pouillot; Patrick Henry; Pascal Motreff; Didier Carrié; Ziad Boueri; Loic Belle; Eric Van Belle; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Olivier Barthélémy; Farzin Beygui; Johanne Silvain; Eric Vicaut; Gilles Montalescot
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

View more
  10 in total

1.  Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells.

Authors:  C Horrix; Z Raviv; E Flescher; C Voss; M R Berger
Journal:  Cell Mol Life Sci       Date:  2010-09-16       Impact factor: 9.261

2.  Ebulin l Is Internalized in Cells by Both Clathrin-Dependent and -Independent Mechanisms and Does Not Require Clathrin or Dynamin for Intoxication.

Authors:  Rosario Iglesias; José M Ferreras; Alicia Llorente; Lucía Citores
Journal:  Toxins (Basel)       Date:  2021-01-30       Impact factor: 4.546

Review 3.  Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.

Authors:  José M Ferreras; Lucía Citores; Rosario Iglesias; Pilar Jiménez; Tomás Girbés
Journal:  Toxins (Basel)       Date:  2011-04-29       Impact factor: 4.546

4.  Toxicity of the anti-ribosomal Lectin Ebulin f in lungs and intestines in elderly mice.

Authors:  Manuel Garrosa; Pilar Jiménez; Jesús Tejero; Patricia Cabrero; Damián Cordoba-Diaz; Emiliano J Quinto; Manuel J Gayoso; Tomás Girbés
Journal:  Toxins (Basel)       Date:  2015-02-02       Impact factor: 4.546

Review 5.  Ebulin from dwarf elder (Sambucus ebulus L.): a mini-review.

Authors:  Pilar Jiménez; Jesús Tejero; Damián Cordoba-Diaz; Emiliano J Quinto; Manuel Garrosa; Manuel J Gayoso; Tomás Girbés
Journal:  Toxins (Basel)       Date:  2015-02-25       Impact factor: 4.546

6.  The Cytotoxicity of Elderberry Ribosome-Inactivating Proteins Is Not Solely Determined by Their Protein Translation Inhibition Activity.

Authors:  Chenjing Shang; Qiushi Chen; Anne Dell; Stuart M Haslam; Winnok H De Vos; Els J M Van Damme
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  Isolation and molecular characterization of two lectins from dwarf elder (Sambucus ebulus L.) blossoms related to the Sam n1 allergen.

Authors:  Pilar Jimenez; Patricia Cabrero; José E Basterrechea; Jesús Tejero; Damian Cordoba-Diaz; Tomas Girbes
Journal:  Toxins (Basel)       Date:  2013-10-14       Impact factor: 4.546

Review 8.  Elderberries: a source of ribosome-inactivating proteins with lectin activity.

Authors:  Jesús Tejero; Pilar Jiménez; Emiliano J Quinto; Damián Cordoba-Diaz; Manuel Garrosa; Manuel Cordoba-Diaz; Manuel J Gayoso; Tomás Girbés
Journal:  Molecules       Date:  2015-01-30       Impact factor: 4.411

9.  Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway.

Authors:  Sudarshan Gadadhar; Anjali A Karande
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Diverse profiles of ricin-cell interactions in the lung following intranasal exposure to ricin.

Authors:  Anita Sapoznikov; Reut Falach; Ohad Mazor; Ron Alcalay; Yoav Gal; Nehama Seliger; Tamar Sabo; Chanoch Kronman
Journal:  Toxins (Basel)       Date:  2015-11-17       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.